OVARIAN CARCINOMA, RECURRENT
Clinical trials for OVARIAN CARCINOMA, RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CARCINOMA, RECURRENT trials appear
Sign up with your email to follow new studies for OVARIAN CARCINOMA, RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cells trained to fight ovarian cancer in new trial
Disease control Recruiting nowThis early-phase trial tests a new type of immune cell therapy called CIML NK cells in 18 people with recurrent ovarian cancer that no longer responds to standard chemotherapy. The cells are taken from the patient, trained in a lab to better attack cancer, and then infused into t…
Matched conditions: OVARIAN CARCINOMA, RECURRENT
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for ovarian cancer: targeted drug T-DXd tested after standard treatments fail
Disease control Recruiting nowThis Phase 2 trial tests whether trastuzumab deruxtecan (T-DXd), a targeted antibody-drug conjugate, works better than standard chemotherapy for recurrent ovarian cancer that has stopped responding to PARP inhibitors. About 116 participants whose tumors express the HER2 protein w…
Matched conditions: OVARIAN CARCINOMA, RECURRENT
Phase: PHASE2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC